It is hoped reducing risk early could significantly improve outcomes, public health officials say.
Trending
- Defining New Thresholds for Precisely Mitigating CAR T Toxicity
- DTX3 promotes anti-tumor immunity by inducing PD-L1 ubiquitination and is suppressed by p65/miR-222 in bladder cancer
- Reviewing the CheckMate 9DW Trial of Nivolumab Plus Ipilimumab in Unresectable HCC
- How to Speak With Patients About Potential Changes to Care During Biopsy Needle Delays
- Novel Agent Begins STARLIGHT-1 Dose Expansion in Relapsed/Refractory B-Cell NHL
- Consolidative Radiotherapy Adds Toxicity Without Survival Benefit in SCLC
- RON receptor tyrosine kinase regulates abiraterone resistance in prostate cancer via the methylation-dependent and independent dual functions of DNMT1
- Managing Ipilimumab Dosing and Immune-Related Toxicity in Frontline HCC

